VNDA · Vanda Pharmaceuticals Inc. Common Stock
View on chartInsiders & Stakes
| Mihael Hristos Polymeropoulos President and CEO | ▼ Sell | Open Market | 2,704,496 Shares held | 3/2/2026 | View profile |
| Gunther Birznieks SVP, Business Development | ▼ Sell | Open Market | 494,197 Shares held | 3/2/2026 | View profile |
| Kevin Patrick Moran SVP, CFO & Treasurer | ▼ Sell | Open Market | 411,380 Shares held | 3/2/2026 | View profile |
| Timothy Williams SVP & General Counsel | ▼ Sell | Open Market | 377,450 Shares held | 3/2/2026 | View profile |
| Joakim Wijkstrom SVP, Chief Marketing Officer | ▼ Sell | Open Market | 333,469 Shares held | 3/2/2026 | View profile |
| Richard W. Dugan Director | ▲ Buy | Grant | 219,054 Shares held | 6/4/2026 | View profile |
| Phaedra Chrousos Director | ▲ Buy | Grant | 164,950 Shares held | 6/4/2026 | View profile |
| Anne Sempowski Ward Director | ▲ Buy | Grant | 160,667 Shares held | 6/4/2026 | View profile |
| Tage Honore Director | ▲ Buy | Grant | 135,069 Shares held | 6/4/2026 | View profile |
| Stephen Ray Mitchell Director | ▲ Buy | Grant | 112,846 Shares held | 6/4/2026 | View profile |
| Daniel Patrick McGuire SVP, GC and Secretary | ▲ Buy | Grant | 109,982 Shares held | 6/4/2026 | View profile |
| Charles Cliff Duncan | ▲ Buy | Grant | 98,701 Shares held | 6/4/2026 | View profile |
| Jones Aranthan II Chief Corp. Affairs Officer | ▼ Sell | Open Market | 81,980 Shares held | 9/15/2021 | View profile |
| Watkins Thomas Director | ▼ Sell | Open Market | 63,064 Shares held | 6/2/2022 | View profile |
Transaction History
| Daniel Patrick McGuire | ▲ Buy | Grant | 80,000 | $0 | 6/4/2026 |
| Phaedra Chrousos | ▲ Buy | Grant | 41,600 | $0 | 6/4/2026 |
| Charles Cliff Duncan | ▲ Buy | Grant | 41,600 | $0 | 6/4/2026 |
| Richard W. Dugan | ▲ Buy | Grant | 41,600 | $0 | 6/4/2026 |
| Anne Sempowski Ward | ▲ Buy | Grant | 41,600 | $0 | 6/4/2026 |
| Tage Honore | ▲ Buy | Grant | 41,600 | $0 | 6/4/2026 |
| Stephen Ray Mitchell | ▲ Buy | Grant | 41,600 | $0 | 6/4/2026 |
| Stephen Ray Mitchell | ▼ Sell | Gift | 25,836 | $0 | 5/18/2026 |
| Charles Cliff Duncan | ▲ Buy | Grant | 57,101 | $0 | 4/22/2026 |
| Timothy Williams | ▼ Sell | Open Market | 42,434 | $351K | 3/2/2026 |
| Kevin Patrick Moran | ▼ Sell | Open Market | 42,442 | $351K | 3/2/2026 |
| Joakim Wijkstrom | ▼ Sell | Open Market | 30,800 | $255K | 3/2/2026 |
| Mihael Hristos Polymeropoulos | ▼ Sell | Open Market | 156,235 | $1.3M | 3/2/2026 |
| Gunther Birznieks | ▼ Sell | Open Market | 42,431 | $351K | 3/2/2026 |
| Tage Honore | ▼ Sell | Open Market | 30,000 | $241K | 2/23/2026 |
| Timothy Williams | ▲ Buy | Grant | 125,000 | $0 | 2/18/2026 |
| Kevin Patrick Moran | ▲ Buy | Grant | 125,000 | $0 | 2/18/2026 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Grant | 525,000 | $0 | 2/18/2026 |
| Joakim Wijkstrom | ▲ Buy | Grant | 125,000 | $0 | 2/18/2026 |
| Gunther Birznieks | ▲ Buy | Grant | 125,000 | $0 | 2/18/2026 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Open Market | 10,000 | $42K | 8/7/2025 |
| Stephen Ray Mitchell | ▼ Sell | Open Market | 7,000 | $32K | 6/13/2025 |
| Stephen Ray Mitchell | ▲ Buy | Grant | 59,225 | $0 | 6/5/2025 |
| Phaedra Chrousos | ▲ Buy | Grant | 59,225 | $0 | 6/5/2025 |
| Richard W. Dugan | ▲ Buy | Grant | 59,225 | $0 | 6/5/2025 |
| Tage Honore | ▲ Buy | Grant | 59,225 | $0 | 6/5/2025 |
| Anne Sempowski Ward | ▲ Buy | Grant | 59,225 | $0 | 6/5/2025 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Open Market | 9,519 | $42K | 5/21/2025 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Open Market | 481 | $2K | 5/21/2025 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Open Market | 20,000 | $84K | 5/16/2025 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Open Market | 5,000 | $25K | 3/6/2025 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Open Market | 5,000 | $25K | 3/6/2025 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Open Market | 5,000 | $25K | 3/5/2025 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Open Market | 5,000 | $25K | 3/5/2025 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Open Market | 10,000 | $47K | 3/3/2025 |
| Kevin Patrick Moran | ▼ Sell | Tax Withholding | 26,941 | $128K | 3/1/2025 |
| Timothy Williams | ▼ Sell | Tax Withholding | 26,941 | $128K | 3/1/2025 |
| Joakim Wijkstrom | ▼ Sell | Tax Withholding | 15,520 | $74K | 3/1/2025 |
| Gunther Birznieks | ▼ Sell | Tax Withholding | 26,941 | $128K | 3/1/2025 |
| Mihael Hristos Polymeropoulos | ▼ Sell | Tax Withholding | 95,999 | $457K | 3/1/2025 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Open Market | 10,000 | $48K | 2/28/2025 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Open Market | 10,000 | $48K | 2/27/2025 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Open Market | 5,000 | $24K | 2/26/2025 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Open Market | 5,000 | $24K | 2/26/2025 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Open Market | 10,000 | $45K | 2/25/2025 |
| Kevin Patrick Moran | ▲ Buy | Open Market | 2,000 | $9K | 2/21/2025 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Grant | 450,000 | $0 | 2/18/2025 |
| Joakim Wijkstrom | ▲ Buy | Grant | 125,000 | $0 | 2/18/2025 |
| Gunther Birznieks | ▲ Buy | Grant | 125,000 | $0 | 2/18/2025 |
| Kevin Patrick Moran | ▲ Buy | Grant | 125,000 | $0 | 2/18/2025 |
| Timothy Williams | ▲ Buy | Grant | 125,000 | $0 | 2/18/2025 |
| Stephen Ray Mitchell | ▼ Sell | Open Market | 5,000 | $26K | 11/14/2024 |
| Kevin Patrick Moran | ▼ Sell | Open Market | 2,251 | $13K | 7/29/2024 |
| Phaedra Chrousos | ▲ Buy | Grant | 21,887 | $0 | 5/22/2024 |
| Stephen Ray Mitchell | ▲ Buy | Grant | 20,529 | $0 | 5/17/2024 |
| Richard W. Dugan | ▲ Buy | Grant | 20,529 | $0 | 5/17/2024 |
| Tage Honore | ▲ Buy | Grant | 20,529 | $0 | 5/17/2024 |
| Anne Sempowski Ward | ▲ Buy | Grant | 20,529 | $0 | 5/17/2024 |
| Kevin Patrick Moran | ▼ Sell | Open Market | 8,902 | $37K | 3/5/2024 |
| Joakim Wijkstrom | ▼ Sell | Open Market | 9,229 | $39K | 3/5/2024 |
| Mihael Hristos Polymeropoulos | ▼ Sell | Open Market | 24,288 | $100K | 3/5/2024 |
| Timothy Williams | ▼ Sell | Open Market | 8,941 | $37K | 3/5/2024 |
| Gunther Birznieks | ▼ Sell | Open Market | 8,684 | $36K | 3/5/2024 |
| Mihael Hristos Polymeropoulos | ▼ Sell | Open Market | 30,884 | $131K | 3/4/2024 |
| Kevin Patrick Moran | ▼ Sell | Open Market | 5,798 | $26K | 3/4/2024 |
| Joakim Wijkstrom | ▼ Sell | Open Market | 7,498 | $33K | 3/4/2024 |
| Timothy Williams | ▼ Sell | Open Market | 8,147 | $36K | 3/4/2024 |
| Gunther Birznieks | ▼ Sell | Open Market | 8,727 | $37K | 3/4/2024 |
| Gunther Birznieks | ▲ Buy | Grant | 125,000 | $0 | 2/16/2024 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Grant | 450,000 | $0 | 2/16/2024 |
| Timothy Williams | ▲ Buy | Grant | 125,000 | $0 | 2/16/2024 |
| Joakim Wijkstrom | ▲ Buy | Grant | 32,700 | $0 | 2/16/2024 |
| Kevin Patrick Moran | ▲ Buy | Grant | 125,000 | $0 | 2/16/2024 |
| Joakim Wijkstrom | ▼ Sell | Open Market | 3,724 | $22K | 8/21/2023 |
| Stephen Ray Mitchell | ▼ Sell | Open Market | 6,500 | $39K | 8/10/2023 |
| Kevin Patrick Moran | ▼ Sell | Open Market | 1,800 | $11K | 7/28/2023 |
| Kevin Patrick Moran | ▼ Sell | Open Market | 412 | $3K | 7/28/2023 |
| Kevin Patrick Moran | ▼ Sell | Open Market | 16,000 | $101K | 6/15/2023 |
| Timothy Williams | ▼ Sell | Open Market | 14,600 | $96K | 6/13/2023 |
| Richard W. Dugan | ▲ Buy | Grant | 17,307 | $0 | 6/8/2023 |
| Anne Sempowski Ward | ▲ Buy | Grant | 17,307 | $0 | 6/8/2023 |
| Stephen Ray Mitchell | ▲ Buy | Grant | 17,307 | $0 | 6/8/2023 |
| Phaedra Chrousos | ▲ Buy | Grant | 17,307 | $0 | 6/8/2023 |
| Tage Honore | ▲ Buy | Grant | 17,307 | $0 | 6/8/2023 |
| Tage Honore | ▲ Buy | Grant | 26,408 | $0 | 3/15/2023 |
| Gunther Birznieks | ▼ Sell | Open Market | 8,268 | $52K | 3/3/2023 |
| Timothy Williams | ▼ Sell | Open Market | 8,301 | $52K | 3/3/2023 |
| Mihael Hristos Polymeropoulos | ▼ Sell | Open Market | 22,538 | $141K | 3/3/2023 |
| Kevin Patrick Moran | ▼ Sell | Open Market | 5,968 | $37K | 3/3/2023 |
| Joakim Wijkstrom | ▼ Sell | Open Market | 4,113 | $26K | 3/3/2023 |
| Joakim Wijkstrom | ▼ Sell | Open Market | 7,720 | $48K | 3/2/2023 |
| Timothy Williams | ▼ Sell | Open Market | 8,437 | $53K | 3/2/2023 |
| Mihael Hristos Polymeropoulos | ▼ Sell | Open Market | 22,426 | $140K | 3/2/2023 |
| Kevin Patrick Moran | ▼ Sell | Open Market | 7,966 | $50K | 3/2/2023 |
| Gunther Birznieks | ▼ Sell | Open Market | 8,509 | $53K | 3/2/2023 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Grant | 115,000 | $0 | 2/16/2023 |
| Joakim Wijkstrom | ▲ Buy | Grant | 32,700 | $0 | 2/16/2023 |
| Timothy Williams | ▲ Buy | Grant | 32,700 | $0 | 2/16/2023 |
| Kevin Patrick Moran | ▲ Buy | Grant | 32,700 | $0 | 2/16/2023 |
| Gunther Birznieks | ▲ Buy | Grant | 32,700 | $0 | 2/16/2023 |
| Timothy Williams | ▼ Sell | Open Market | 8,000 | $56K | 12/15/2022 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Option Exercise | 75,365 | $235K | 12/6/2022 |
| Mihael Hristos Polymeropoulos | ▼ Sell | Open Market | 48,250 | $512K | 12/6/2022 |
| Kevin Patrick Moran | ▲ Buy | Option Exercise | 7,500 | $23K | 12/6/2022 |
| Kevin Patrick Moran | ▼ Sell | Open Market | 4,792 | $51K | 12/6/2022 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Option Exercise | 74,635 | $233K | 12/5/2022 |
| Mihael Hristos Polymeropoulos | ▼ Sell | Open Market | 47,650 | $506K | 12/5/2022 |
| Gunther Birznieks | ▲ Buy | Option Exercise | 1,250 | $4K | 8/26/2022 |
| Joakim Wijkstrom | ▼ Sell | Open Market | 3,605 | $37K | 8/22/2022 |
| Timothy Williams | ▼ Sell | Open Market | 3,689 | $38K | 8/15/2022 |
| Timothy Williams | ▼ Sell | Open Market | 4,611 | $47K | 8/15/2022 |
| Kevin Patrick Moran | ▼ Sell | Open Market | 2,239 | $25K | 7/28/2022 |
| Anne Sempowski Ward | ▲ Buy | Grant | 12,006 | $0 | 6/16/2022 |
| Stephen Ray Mitchell | ▲ Buy | Grant | 12,006 | $0 | 6/16/2022 |
| Richard W. Dugan | ▲ Buy | Grant | 12,006 | $0 | 6/16/2022 |
| Phaedra Chrousos | ▲ Buy | Grant | 12,006 | $0 | 6/16/2022 |
| Stephen Ray Mitchell | ▼ Sell | Open Market | 2,700 | $26K | 6/13/2022 |
| Watkins Thomas | ▲ Buy | Option Exercise | 15,000 | $62K | 6/2/2022 |
| Watkins Thomas | ▼ Sell | Open Market | 6,441 | $64K | 6/2/2022 |
| Richard W. Dugan | ▲ Buy | Option Exercise | 15,000 | $62K | 5/31/2022 |
| Richard W. Dugan | ▼ Sell | Open Market | 6,500 | $64K | 5/31/2022 |
| Timothy Williams | ▼ Sell | Open Market | 12,060 | $134K | 3/2/2022 |
| Joakim Wijkstrom | ▼ Sell | Open Market | 6,974 | $78K | 3/2/2022 |
| Mihael Hristos Polymeropoulos | ▼ Sell | Open Market | 29,588 | $330K | 3/2/2022 |
| Kevin Patrick Moran | ▼ Sell | Open Market | 8,832 | $100K | 3/2/2022 |
| Gunther Birznieks | ▼ Sell | Open Market | 11,517 | $130K | 3/2/2022 |
| Mihael Hristos Polymeropoulos | ▼ Sell | Open Market | 7,508 | $84K | 3/1/2022 |
| Kevin Patrick Moran | ▼ Sell | Open Market | 3,473 | $39K | 3/1/2022 |
| Gunther Birznieks | ▼ Sell | Open Market | 4,084 | $46K | 3/1/2022 |
| Timothy Williams | ▲ Buy | Grant | 32,700 | $0 | 2/28/2022 |
| Joakim Wijkstrom | ▲ Buy | Grant | 32,700 | $0 | 2/28/2022 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Grant | 115,000 | $0 | 2/28/2022 |
| Kevin Patrick Moran | ▲ Buy | Grant | 32,700 | $0 | 2/28/2022 |
| Gunther Birznieks | ▲ Buy | Grant | 32,700 | $0 | 2/28/2022 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Option Exercise | 71,676 | $350K | 12/1/2021 |
| Mihael Hristos Polymeropoulos | ▼ Sell | Open Market | 46,200 | $739K | 12/1/2021 |
| Mihael Hristos Polymeropoulos | ▲ Buy | Option Exercise | 78,324 | $382K | 11/30/2021 |
| Mihael Hristos Polymeropoulos | ▼ Sell | Open Market | 50,000 | $824K | 11/30/2021 |
| Jones Aranthan II | ▼ Sell | Open Market | 16,824 | $277K | 9/15/2021 |
| Jones Aranthan II | ▲ Buy | Option Exercise | 4,277 | $52K | 9/15/2021 |
| Jones Aranthan II | ▲ Buy | Option Exercise | 7,842 | $89K | 9/15/2021 |
| Stephen Ray Mitchell | ▲ Buy | Option Exercise | 5,985 | $63K | 9/9/2021 |
| Stephen Ray Mitchell | ▲ Buy | Option Exercise | 13,124 | $167K | 9/9/2021 |
| Stephen Ray Mitchell | ▼ Sell | Open Market | 19,109 | $320K | 9/9/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Oppenheimer Launches Coverage on Vanda Pharmaceuticals
Oppenheimer has begun covering Vanda Pharmaceuticals, issuing an outperform rating and a $10 price target. The target sits near the middle of the analyst range and below the 52‑week high, suggesting a cautious upside view. The stock is trading above its $5.21 support level with an RSI of 41.6, indicating room for movement.
Oppenheimer Launches Coverage on Vanda Pharmaceuticals. Oppenheimer has begun covering Vanda Pharmaceuticals, issuing an outperform rating and a $10 price target. The target sits near the middle of the analyst range and below the 52‑week high, suggesting a cautious upside view. The stock is trading above its $5.21 support level with an RSI of 41.6, indicating room for movement.